TITLE

The Role of Antimalarials in the Exacerbation of Psoriasis: A Systematic Review

AUTHOR(S)
Herman, Sari M.; Shin, Michael H.; Holbrook, Anne; Rosenthal, Donald
PUB. DATE
July 2006
SOURCE
American Journal of Clinical Dermatology;2006, Vol. 7 Issue 4, p249
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To critically review the body of literature that refutes or supports the role of antimalarials in the exacerbation of psoriasis. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were reviewed to identify English-language publications from 1966–2005 examining the role of antimalarials in the exacerbation of psoriasis. A total of 374 articles were identified, of which 32 studies met the inclusion criteria. All available clinical trials or reported cases of the use of antimalarials for patients with psoriasis were included. Data from clinical studies were summarized according to the level of evidence and the outcome of the study. Data were entered into a standardized data extraction form by two independent reviewers. RESULTS AND C: onclusion: No randomized trial evidence was found. Only one cohort study was available for review. A total of 31 case series and case reports were obtained. There is no strong evidence to refute or support the role of antimalarials in the exacerbation of psoriasis. Controlled trials of antimalarial therapy and its effect on psoriasis are warranted.
ACCESSION #
22027036

 

Related Articles

  • Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus. Wozniacka, Anna; McCauliffe, Daniel P. // American Journal of Clinical Dermatology;2005, Vol. 6 Issue 1, p1 

    Antimalarials have been used to treat cutaneous and systemic lupus erythematosus (LE) for decades. Although controlled studies comparing the efficacy of antimalarials versus placebo and other treatments are generally lacking, many case reports and series support the therapeutic efficacy of these...

  • Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. Plowe, Christopher V.; Kublin, James G.; Dzinjalamala, Fraction K.; Kamwendo, Deborah S.; Mukadam, Rabia A. G.; Chimpeni, Phillips; Molyneux, Malcolm E.; Taylor, Terrie E. // BMJ: British Medical Journal (International Edition);3/6/2004, Vol. 328 Issue 7439, p545 

    Objective: To measure the efficacy of sulfadoxine-pyrimethamine treatment of falciparum malaria in Malawi from 1998 to 2002, after a change from chloroquine to sulfadoxine-pyrimethamine as first line treatment in that country in 1993. Design: Prospective open label drug efficacy study. Setting:...

  • Synthesis and Antimalarial Activity of 1,2,4,5-Tetraoxanes. Yuxiang Dong, J.D. // Mini Reviews in Medicinal Chemistry;Apr2002, Vol. 2 Issue 2, p113 

    Methods for formation of 1,2,4,5-tetraoxanes are summarized and antimalarial activities of 1,2,4,5-tetraoxanes are discussed.

  • Monitoring Antimalarial Drug Efficacy. Ringwald, P. // Clinical Infectious Diseases;4/15/2004, Vol. 38 Issue 8, p1192 

    Presents letters to the editor on antimalarial drug efficacy, published in the April 15, 2004 issue of the journal "Clnical Infectious Diseases." Effects of the chemical compound sulfadoxine-pyrimethamine therapy; Results of clinical trials for drug resistance; Antimalarial drug efficacy in low...

  • Case report: Life-threatening hypoglycaemia associated with sulfadoxinepyrimethamine,a commonly used antimalarial drug Fairhurst, R.M.; Sadou, B.; Guindo, A.; Diallo, D.A.; Doumbo, O.K.; Wellems, T.E. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Sep2003, Vol. 97 Issue 5, p595 

    Abstract: Due to chloroquine resistance, several African countries have changed their first-line malaria treatmentto sulfadoxine-pyrimethamine (SP). In this report, we present a case of hypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to...

  • The problem with upward mobility. Gudjonsson, Johann E.; Elder, James T. // Nature Medicine;Jul2007, Vol. 13 Issue 7, p786 

    The article presents a study related to psoriasis, a chronic skin disease characterized by dry patches covered with scales. Although generally not life threatening, psoriasis occurs especially on the scalp and ears and genitalia and the skin over bony prominences. In this study, researchers show...

  • CLINICAL EXPERIENCE WITH LONGTERM USE OF BIOLOGIC AGENTS: EFFICACY. Burfeind, Daniel B. // Dermatology Nursing;Apr2006, Vol. 18 Issue 2, p181 

    The article presents a discussion on the effectiveness of the long-term use of biologic agents in the treatment of psoriasis. An estimated 4.5 to 7 million people in the United States suffer from psoriasis and the treatment cost for approximately 1.4 million individuals is $649.6 million....

  • IN THIS ISSUE... Michaëlson, Gerd // Acta Dermato-Venereologica;2008, Vol. 88 Issue 2, p99 

    The article discusses palmoplantar pustular psoriasis (PPP), the use of the drug efalizumab during its treatment and the inconsistency in PPP terminology. PPP commonly afflicts women and smokers. It targets the palmoplantar sweat duct causing intense inflammation. Although difficult to treat,...

  • Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Araiza-Casillas, R.; C�rdenas, F.; Morales, Y.; Cardiel, M. H. // Lupus;2004, Vol. 13 Issue 2, p119 

    Antimalarials are very useful drugs in the treatment of various rheumatic diseases. One of their main side effects is ocular toxicity, specifically retinopathy. Our objective was to identify risk factors associated with chloroquine retinopathy. A single, trained evaluator reviewed patient...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics